News brief
On 2026-09-03, according to Xiniu Data, Superluminal Medicines completed Series B financing, raising USD 60 million. Investors were lead investor BVF Partners, RA Capital Management, Perceptive Advisors, NVIDIA and others. The company is a provider of U.S. AI generation drugs services.
Connected profiles
Explore
Sources · 0Sources & provenance
English text is maintained separately from the original record. Consult the original source before citing a fact.
No source links are available for this profile.
Original source text
Names may use phonetic renderings when no English name is supplied. The original wording is retained below.
2026年9月3日，据烯牛数据报道，Superluminal Medicines完成B轮融资，金额6000万美元。投资方为BVF Partners领投，RA Capital Management，Perceptive Advisors，NVIDIA等。该公司为美国AI生成药物服务商。